Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group.
Roos-Weil D, Nguyen-Khac F, Chevret S, Touzeau C, Roux C, Lejeune J, Cosson A, Mathis S, Feugier P, Leprêtre S, Béné MC, Baron M, Raynaud S, Struski S, Eclache V, Sutton L, Lesty C, Merle-Béral H, Cymbalista F, Ysebaert L, Davi F, Leblond V; FILO working group. Roos-Weil D, et al. Among authors: touzeau c. Genes Chromosomes Cancer. 2018 Nov;57(11):533-540. doi: 10.1002/gcc.22650. Epub 2018 Sep 11. Genes Chromosomes Cancer. 2018. PMID: 30203893 Free article.
Cereblon expression in multiple myeloma: not ready for prime time.
Lodé L, Amiot M, Maiga S, Touzeau C, Menard A, Magrangeas F, Minvielle S, Pellat-Deceunynck C, Bene MC, Moreau P. Lodé L, et al. Among authors: touzeau c. Br J Haematol. 2013 Oct;163(2):282-4. doi: 10.1111/bjh.12478. Epub 2013 Jul 17. Br J Haematol. 2013. PMID: 23862718 Free article. No abstract available.
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
Roussel M, Merlini G, Chevret S, Arnulf B, Stoppa AM, Perrot A, Palladini G, Karlin L, Royer B, Huart A, Macro M, Morel P, Frenzel L, Touzeau C, Boyle E, Dorvaux V, Le Bras F, Lavergne D, Bridoux F, Jaccard A. Roussel M, et al. Among authors: touzeau c. Blood. 2020 Apr 30;135(18):1531-1540. doi: 10.1182/blood.2019004369. Blood. 2020. PMID: 32108228 Free article. Clinical Trial.
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience.
Caulier A, Roussel M, Morel P, Lombion N, Branco B, Galtier J, Hulin C, Perrot A, Richez V, Michaud AV, Touzeau C, Doyen C, Mariette C, Caillot D, Harel S, Lenain P, Ivanoff S, Fontan J, Stoppa AM, Manier S, Garderet L, Leleu X, Marolleau JP, Arnulf B, Avet-Loiseau H, Royer B. Caulier A, et al. Among authors: touzeau c. Blood. 2021 Dec 23;138(25):2686-2695. doi: 10.1182/blood.2021011285. Blood. 2021. PMID: 34479366 Free article.
Molecular Signature of 18F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study.
Alberge JB, Kraeber-Bodéré F, Jamet B, Touzeau C, Caillon H, Wuilleme S, Béné MC, Kampfenkel T, Sonneveld P, van Duin M, Avet-Loiseau H, Corre J, Magrangeas F, Carlier T, Bodet-Milin C, Chérel M, Moreau P, Minvielle S, Bailly C. Alberge JB, et al. Among authors: touzeau c. J Nucl Med. 2022 Jul;63(7):1008-1013. doi: 10.2967/jnumed.121.262884. Epub 2022 Jan 27. J Nucl Med. 2022. PMID: 35086897 Free PMC article.
Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.
Bodet-Milin C, Touzeau C, Leux C, Sahin M, Moreau A, Maisonneuve H, Morineau N, Jardel H, Moreau P, Gallazini-Crépin C, Gries P, Gressin R, Harousseau JL, Mohty M, Moreau P, Kraeber-Bodere F, Le Gouill S. Bodet-Milin C, et al. Among authors: touzeau c. Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1633-42. doi: 10.1007/s00259-010-1469-2. Epub 2010 Apr 29. Eur J Nucl Med Mol Imaging. 2010. PMID: 20428863
Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation.
Fouquet G, Hebraud B, Garciaz S, Stoppa AM, Roussel M, Caillot D, Chrétien ML, Arnulf B, Szalat R, Garderet L, Benajiba L, Pegourie B, Regny C, Royer B, Caulier A, Touzeau C, Tessoulin B, Fermand JP, Facon T, Attal M, Loiseau HA, Moreau P, Leleu X. Fouquet G, et al. Among authors: touzeau c. J Cancer. 2014 Mar 11;5(3):248-52. doi: 10.7150/jca.8541. eCollection 2014. J Cancer. 2014. PMID: 24665349 Free PMC article.
Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
Sortais C, Lok A, Tessoulin B, Gastinne T, Mahé B, Dubruille V, Blin N, Touzeau C, Moreau A, Bossard C, Peterlin P, Garnier A, Guillaume T, Le Bourgeois A, Chevallier P, Moreau P, Leux C, Le Gouill S. Sortais C, et al. Among authors: touzeau c. Ann Hematol. 2020 Jul;99(7):1595-1604. doi: 10.1007/s00277-020-04025-2. Epub 2020 May 16. Ann Hematol. 2020. PMID: 32417940
186 results